Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diwu Fengshian
- Development stage
- Unknown
- Lead developer
- Hubei University of Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Diwu Fengshian is a traditional Chinese medicine (TCM) preparation developed by the Hubei University of Traditional Chinese Medicine, specifically designed for the treatment of rheumatoid arthritis (RA). The formulation is primarily based on the medicinal herb *Gynura japonica* (Thunb.) Juel, commonly known as "Diwu" in the Hubei region. It is typically indicated for RA patients categorized under the "cold-dampness obstruction" syndrome in TCM diagnostics. Pharmacologically, Diwu Fengshian acts by suppressing the inflammatory response; it inhibits the expression of key pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It also modulates the NF-κB signaling pathway, which plays a central role in the pathogenesis of RA. Clinical research, primarily conducted in China, suggests that the drug effectively reduces joint swelling and pain while improving the quality of life for patients with chronic inflammatory joint diseases.
- Brand names
- Diwu Fengshian
- Other names
- Diwu Fengshian CapsuleDiwu Fengshian Granules地乌风湿安
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)NF-κBIL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Diwu Fengshian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diwu Fengshian.